 As Executive Director of ICRF Toronto, I have the privilege of working with a community of compassionate and dedicated staff, medical experts, researchers and volunteers whose shared mission is to find treatments and cures for cancer.
It is an honour to work for a cause that impacts the entire world. Throughout the pandemic cancer has unfortunately remained an issue that touches all of us. Israel Cancer Research Fund continues to work tirelessly to address the impact of cancer on our world.
I am so grateful to our ICRF family of supporters and I look forward to connecting with you in 2022. Please connect with me directly at jouaknine@icrf.ca - I'd love to get to know you!
Thank you for your support and best wishes for a happy and healthy 2022!
Jennifer Ouaknine
Executive Director, ICRF Toronto
|
|
|
|
HPV Vaccine Protects Against Cervical Cancer
ICRF interviews Dr. Rachel A. Katzenellenbogen, Chief, Division of Adolescent Medicine, Indiana University School of Medicine, on the importance of the HPV (human papillomavirus) vaccine.
|
|
Can you describe the relationship between cervical cancer and HPV?
There are well over 200 known types of HPVs, and it is a very common infection. A subset of them, called high-risk HPVs, are associated with cancers that can result from a long-term infection. There are more than a dozen high-risk HPVs, which cause nearly 100 percent of all cervical cancers. In addition, HPV is associated with head and neck cancer and other cancers that can be inhibited by the vaccine.
Read the full interview
|
|
- Cervical cancer often presents a special challenge because symptoms are not always apparent, especially in the earliest stages. Therefore it is highly recommended to begin regular cervical cancer screenings at age 21.
- The HPV vaccine is a vital tool for preventing cervical cancer since most cervical cancers are caused by the virus. The introduction of the HPV Gardasil® in 2006 has rendered the vast majority of cervical cancers preventable.
- Cervical cancer is most frequently diagnosed in women between the ages of 35 and 44. About 20 percent of cervical cancers are diagnosed in women over 65.
- The American Cancer Society estimates that in 2021, 14,480 cases of invasive cervical cancer were diagnosed and that about 4,300 women died from the disease.
- Treatments may include surgery, radiation, and chemotherapy.
Source: American Cancer Society, World Health Organization
|
|
ICRF Researcher Behind World's First 3D Tumor Model
Professor Ronit Satchi-Fainaro's research will improve the treatment and development of new drugs to combat glioblastoma, the deadliest type of brain cancer.
|
|
|
We have been reading all over the media that your lab has “printed” the first 3D living malignant brain tumor. Can you describe this incredible development?
Many drugs show promising results in laboratory research, but eventually fail in clinical trials because the success achieved in the laboratory cannot be recreated in real people. We hypothesize that one main reason for this translational gap is that current cancer models are inadequate. The reason is that cancer, like all tissues, behaves very differently on a plastic surface than it does in the human body. We understood that growing all types of cancer on identical plastic surfaces is not an optimal simulation of the clinical environment.
Read the full article
|
|
|
ICRF Toronto
We are pleased to welcome Dr. Neil Berinstein to the ICRF Board of Directors. Read his full bio here.
|
|
|
|
Run With Team ICRF In New York!
ICRF has been selected to be an official Charity Partner of the United Airlines NYC Half Marathon on March 20, 2022.
Run with Team ICRF to raise funds for innovative cancer research in Israel and help others imagine a day where cancer no longer causes suffering for patients and their loved ones.
To learn more about a guaranteed fundraising entry, how you can help raise money for the team if you already have a confirmed entry, or how you can sponsor an ICRF runner, please visit the USA website or contact New York Executive Director Alan Herman at alan.herman@icrfonline.org to learn more!
|
|
|
ICRF Toronto 2022 event updates coming soon...
|
|
Technion researchers have developed a trailblazing "Nano-Ghost" platform that allows for the reduction of drug dosage by a factor of a million, while maintaining the same effect, and avoiding damage to healthy tissue. (Israel Hayom)
Read more
|
|
|
Your lasting legacy through ICRF will impact cancer research in Israel for generations to come. With a planned gift to Israel Cancer Research Fund, you can leave a philanthropic legacy that will help those touched by cancer – now and for years to come. Whether you would like to put your donation to work today or in the future, there are a variety of opportunities for making a legacy commitment to ICRF.
Please contact Jennifer Ouaknine at jouaknine@icrf.ca or at 647-973-4273 to learn how you can create a lasting impact on the future of cancer research. The Answer to Cancer is Research!
|
|
|
|
|
